ITRM - Iterum Therapeutics plc

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Iterum Therapeutics plc

Harcourt Centre
Block 2, Floor 3 Harcourt Street
Dublin 2
Ireland
353 1 903 8920
http://www.iterumtx.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees48

Key Executives

NameTitlePayExercisedYear Born
Mr. Corey N. FishmanPres, CEO & Director803.48kN/A1965
Ms. Judith M. MatthewsChief Financial Officer432.88kN/A1970
Dr. Michael W. DunneChief Scientific Officer549.06kN/A1960
Mr. Benjamin M. PeVP of OperationsN/AN/AN/A
Louise BarrettSec.N/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a novel penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was founded in 2015 and is headquartered in Dublin, Ireland.

Corporate Governance

Iterum Therapeutics plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.